Blog Posts

Assessing The Value Of Wearables In Interventional Clinical Trials

Posted May 24, 2018| Prem Meyyan

Originally published in: Clinical Leader

Health-Wearable-Smart-Watch

Advancements in biosensor technology are becoming increasingly common in the consumer space, with wrists adorned with Fitbits or similar devices, clothing embedded with “intelligent” fibers, and personal safety devices seen in healthcare facilities across the nation. Our culture is increasingly accustomed to tracking health metrics through smartphones and simple recreational wearables. In the pharmaceutical space, we are now seeing where success in the consumer segment can translate to value-adds for clinical trials.

In traditional pharmaceutical interventional clinical trials, collection of data for primary and secondary endpoints (objective and/or subjective) must take place in a clinical setting to maximize quality control and meet FDA requirements. In some cases, the FDA allows secondary endpoint data to be collected remotely (usually in the home setting), often through questionnaires completed by patients and/or their caregivers. Such data are usually subjective and as such are typically not sufficient for primary endpoint analysis in interventional trials. Novel wearable biosensors change the calculus by creating the opportunity to collect objective data outside the clinic.

 

Tags: , , , , , ,

Related Resources

Read More

Life Insurers Should Make Bold Moves to Capture Millennials

Why John Hancock’s recent Vitality Program points to a call for creativity and digitization in a historically staid industry. An […]

Read More

Three Key Actions Health + Life Science Execs Overlook During Annual Planning

As Health and Life Science executives look to 2019, they should ensure their strategic and business plans thoroughly consider external […]

Read More

Competitive Intelligence (CI) Dictionary

Competitive Intelligence is the collection and analysis of information to anticipate competitive activity, see past market disruptions and dispassionately interpret […]

z

Subscribe to our mailing list for our latest updates: